The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis
IntroductionCancer represents a significant global public health concern. In recent years, the incidence of cancer has been on the rise worldwide due to various factors, including diet, environment, and an aging population. Simultaneously, advancements in tumor molecular biology and genomics have le...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1345737/full |
| _version_ | 1827277954095251456 |
|---|---|
| author | Yujie Huang Daitian Zheng Zhongming Zhou Haiting Wang Yanpo Li Huihui Zheng Jianhui Tan Jingyao Wu Qiuping Yang Huiting Tian Liuming Lin Zhiyang Li Tianyu Li |
| author_facet | Yujie Huang Daitian Zheng Zhongming Zhou Haiting Wang Yanpo Li Huihui Zheng Jianhui Tan Jingyao Wu Qiuping Yang Huiting Tian Liuming Lin Zhiyang Li Tianyu Li |
| author_sort | Yujie Huang |
| collection | DOAJ |
| description | IntroductionCancer represents a significant global public health concern. In recent years, the incidence of cancer has been on the rise worldwide due to various factors, including diet, environment, and an aging population. Simultaneously, advancements in tumor molecular biology and genomics have led to a shift from systemic chemotherapy focused on disease sites and morphopathology towards precise targeted therapy for driver gene mutations. Therefore, we propose a comprehensive review aimed at exploring the research hotspots and directions in the field of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant cancers over the past decade, providing valuable insights for cancer treatment strategies. Specifically, we aim to present an intellectual landscape using data obtained from the Web of Science (WoS) regarding KRAS mutation.MethodsBibliometrix, VOSviewer, CiteSpace, and HistCite were employed to conduct scientometric analyses on national publications, influential authors, highly cited articles, frequent keywords, etc.ResultsA total of 16,609 publications met the screening criteria and exhibited a consistent annual growth trend overall. Among 102 countries/regions, the United States occupied the vast majority share of the published volume. The journal Oncotarget had the highest circulation among all scientific publications. Moreover, the most seminal articles in this field primarily focus on biology and targeted therapies, with overcoming drug resistance being identified as a future research direction.ConclusionThe findings of the thematic analysis indicate that KRAS mutation in lung cancer, the prognosis following B-Raf proto-oncogene, serine/threonine kinase (BRAF) or rat sarcoma (RAS) mutations, and anti-epidermal growth factor receptor (EGFR)-related lung cancer are the significant hotspots in the given field. Considering the significant advancements made in direct targeting drugs like sotorasib, it is anticipated that interest in cancers associated with KRAS mutations will remain steadfast. |
| first_indexed | 2024-04-24T07:45:00Z |
| format | Article |
| id | doaj.art-c8b53ffbe91c4f55a4bda44adffdd67d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T07:45:00Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-c8b53ffbe91c4f55a4bda44adffdd67d2024-04-19T04:32:59ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-04-011410.3389/fonc.2024.13457371345737The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysisYujie HuangDaitian ZhengZhongming ZhouHaiting WangYanpo LiHuihui ZhengJianhui TanJingyao WuQiuping YangHuiting TianLiuming LinZhiyang LiTianyu LiIntroductionCancer represents a significant global public health concern. In recent years, the incidence of cancer has been on the rise worldwide due to various factors, including diet, environment, and an aging population. Simultaneously, advancements in tumor molecular biology and genomics have led to a shift from systemic chemotherapy focused on disease sites and morphopathology towards precise targeted therapy for driver gene mutations. Therefore, we propose a comprehensive review aimed at exploring the research hotspots and directions in the field of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant cancers over the past decade, providing valuable insights for cancer treatment strategies. Specifically, we aim to present an intellectual landscape using data obtained from the Web of Science (WoS) regarding KRAS mutation.MethodsBibliometrix, VOSviewer, CiteSpace, and HistCite were employed to conduct scientometric analyses on national publications, influential authors, highly cited articles, frequent keywords, etc.ResultsA total of 16,609 publications met the screening criteria and exhibited a consistent annual growth trend overall. Among 102 countries/regions, the United States occupied the vast majority share of the published volume. The journal Oncotarget had the highest circulation among all scientific publications. Moreover, the most seminal articles in this field primarily focus on biology and targeted therapies, with overcoming drug resistance being identified as a future research direction.ConclusionThe findings of the thematic analysis indicate that KRAS mutation in lung cancer, the prognosis following B-Raf proto-oncogene, serine/threonine kinase (BRAF) or rat sarcoma (RAS) mutations, and anti-epidermal growth factor receptor (EGFR)-related lung cancer are the significant hotspots in the given field. Considering the significant advancements made in direct targeting drugs like sotorasib, it is anticipated that interest in cancers associated with KRAS mutations will remain steadfast.https://www.frontiersin.org/articles/10.3389/fonc.2024.1345737/fullKRAScancerscientometricsBibliometrixVOSviewerCitespace |
| spellingShingle | Yujie Huang Daitian Zheng Zhongming Zhou Haiting Wang Yanpo Li Huihui Zheng Jianhui Tan Jingyao Wu Qiuping Yang Huiting Tian Liuming Lin Zhiyang Li Tianyu Li The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis Frontiers in Oncology KRAS cancer scientometrics Bibliometrix VOSviewer Citespace |
| title | The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis |
| title_full | The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis |
| title_fullStr | The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis |
| title_full_unstemmed | The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis |
| title_short | The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis |
| title_sort | research advances in kirsten rat sarcoma viral oncogene homolog kras related cancer during 2013 to 2022 a scientometric analysis |
| topic | KRAS cancer scientometrics Bibliometrix VOSviewer Citespace |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1345737/full |
| work_keys_str_mv | AT yujiehuang theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT daitianzheng theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT zhongmingzhou theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT haitingwang theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT yanpoli theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT huihuizheng theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT jianhuitan theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT jingyaowu theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT qiupingyang theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT huitingtian theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT liuminglin theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT zhiyangli theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT tianyuli theresearchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT yujiehuang researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT daitianzheng researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT zhongmingzhou researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT haitingwang researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT yanpoli researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT huihuizheng researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT jianhuitan researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT jingyaowu researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT qiupingyang researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT huitingtian researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT liuminglin researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT zhiyangli researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis AT tianyuli researchadvancesinkirstenratsarcomaviraloncogenehomologkrasrelatedcancerduring2013to2022ascientometricanalysis |